MetaCap

Nanobiotix S.A. (NBTX) vs Tyra Biosciences (TYRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nanobiotix S.A. (NBTX) has outperformed Tyra Biosciences (TYRA) over the past year, gaining 26.6% versus a loss of 4.7%. Over five years, NBTX leads with a +214.0% price change compared with -15.7% for TYRA. Tyra Biosciences is the larger company by market cap ($1.39 billion vs $1.35 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NBTX+26.61%TYRA-4.73%
+172%+75%-21%
Nov 21, 20251 yearNov 20, 2026
NBTX+185.87%TYRA-16.17%
+482%+189%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NBTX versus TYRA key metrics
MetricNBTXTYRA
Share price$26.50$20.12
Market cap$1.35B$1.39B
1-day change-2.98%+1.98%
YTD return+14.62%-23.47%
1-year return+26.61%-4.73%
5-year return+213.98%-15.71%
EPS (TTM)$-1.27$-2.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-119.95M
52-week high$57.14$40.65
52-week low$19.14$18.25
Distance from 52-week high-53.62%-50.50%
Analyst consensusnonestrong_buy
Avg. price target upside+101.06%+135.83%
Average volume148.94K852.56K
Shares outstanding50.95M69.08M
Employees9887
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NBTX has outperformed TYRA by 31.3 percentage points over the past year.

About Nanobiotix S.A.

NBTX stock →

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.

Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees

About Tyra Biosciences

TYRA stock →

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

NBTX vs TYRA FAQ

Which is bigger, Nanobiotix S.A. or Tyra Biosciences?

Tyra Biosciences (TYRA) is larger, with a market capitalization of $1.39B compared with $1.35B for Nanobiotix S.A. (NBTX).

Which stock has performed better over the past year, NBTX or TYRA?

NBTX returned +26.61% over the past 12 months, compared with -4.73% for TYRA (price return, excluding dividends). Past performance does not predict future results.

Are Nanobiotix S.A. and Tyra Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons